Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics


Sage Therapeutics, Inc. (SAGE)

Today's Latest Price: $60.82 USD

1.92 (3.26%)

Updated Sep 25 4:15pm

Add SAGE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

SAGE Stock Summary

  • SAGE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,564.74 -- higher than 98.56% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 354.98, Sage Therapeutics Inc has a higher such ratio than 98.62% of stocks in our set.
  • Revenue growth over the past 12 months for Sage Therapeutics Inc comes in at 452.76%, a number that bests 98.47% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Sage Therapeutics Inc, a group of peers worth examining would be PRTA, RESN, HRTX, MXL, and WATT.
  • SAGE's SEC filings can be seen here. And to visit Sage Therapeutics Inc's official web site, go to www.sagerx.com.
SAGE Daily Price Range
SAGE 52-Week Price Range

SAGE Stock Price Chart Technical Analysis Charts


SAGE Price/Volume Stats

Current price $60.82 52-week high $155.33
Prev. close $58.90 52-week low $25.01
Day low $58.74 Volume 355,377
Day high $60.94 Avg. volume 947,112
50-day MA $51.75 Dividend yield N/A
200-day MA $49.78 Market Cap 3.16B

Sage Therapeutics, Inc. (SAGE) Company Bio


Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.


SAGE Latest News Stream


Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream


Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Sage Therapeutics Upgraded on Potential for Depression Drug

Wedbush analyst Laura Chico upgraded Sage Therapeutics to outperform on the potential of a developmental drug to treat depression.

The Street | September 11, 2020

Benzinga's Top Upgrades, Downgrades For September 11, 2020

Upgrades * According to Wedbush, the prior rating for Sage Therapeutics Inc (NASDAQ: SAGE) was changed from Neutral to Outperform. Sage Therapeutics earned $2.08 in the second quarter, compared to $3.28 in the year-ago quarter. The current stock performance of Sage Therapeutics shows a 52-week-high of $167.82 and a 52-week-low of $25.01. Moreover, at the end of the last trading period, the closing price was at $54.25. * According to Stifel, the prior rating for Photronics Inc (NASDAQ: PLAB) was changed from Hold to Buy. For the third quarter, Photronics had an EPS of $0.17, compared to year-ago quarter EPS of $0.10. At the moment, the stock has a 52-week-high of $16.75 and a 52-week-low of $8.31. Photronics closed at $8.73 at the end of the last trading period. * For ACM Research In...

Yahoo | September 11, 2020

Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Yahoo | September 11, 2020

Sage Therapeutics’ FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host “FutureCast: An R&D Portfolio Review” to discuss the Company’s research and development strategy, and clinical progress in its key depression, neurology, and neuropsychiatry franchise programs. “The team at Sage continues to follow the scien

Business Wire | September 10, 2020

Sage Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m. ET. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sage

Business Wire | September 1, 2020

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo 22.35%
3-mo 45.61%
6-mo 111.77%
1-year -57.39%
3-year -3.28%
5-year 49.25%
YTD -15.75%
2019 -24.64%
2018 -41.84%
2017 222.58%
2016 -12.42%
2015 59.29%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8259 seconds.